[NCL in animal models].
Neuronal ceroid lipofuscinoses (NCL) are severe neurodegenerative diseases leading to early death. They belong to the group of lysosomal storage diseases. Epileptic seizures, dementia and motor deficits are frequent symptoms which are to be found prior to a total dismantling of personality and death. At present 10 subtypes of NCL can be distinguished from which the genetic defect is known in eight. The encoded proteins are soluble or membrane proteins whose function is still unclear in most cases. The investigation of the pathology and pathophysiology of NCL is highly dependent on animal models. Mouse models existing for all forms with a known genetic defect play a prominent role. Unfortunately, the retinal phenotype of some mouse models is milder than in humans rendering the appreciation of a positive therapeutic effect more difficult. Because of the severity of NCL, therapy strategies only established in a mouse model will be transferred to humans very quickly.
Rüther
K
K
Arbeitsbereich Strabologie/Neuroophthalmologie, Augenklinik, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany. Klaus.ruether@charite.de
D000818:Animals; D002648:Child; D004195:Disease Models, Animal; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics; D006801:Humans; D008297:Male; D051379:Mice; D009472:Neuronal Ceroid-Lipofuscinoses / Q000150:complications / Q000503:physiopathology*; D014786:Vision Disorders / Q000209:etiology / Q000503:physiopathology*
Hum Mol Genet. 2001 Sep 15;10(19):2123-31
11590129
Pediatr Neurol. 2007 Jun;36(6):411-3
17560505
Mol Genet Metab. 2006 Apr;87(4):341-8
16386934
J Clin Invest. 1998 Jul 15;102(2):361-70
9664077
Brain Pathol. 2006 Apr;16(2):110-6
16768750
Biochem Biophys Res Commun. 2005 Feb 11;327(2):541-7
15629147
J Inherit Metab Dis. 2005;28(6):1065-80
16435200
J Neurosci Res. 1999 Aug 15;57(4):551-6
10440905
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13566-71
11717424
Neurobiol Dis. 2006 May;22(2):284-93
16412658
Acta Neurol Scand. 1997 Jan;95(1):1-8
9048977
Brain. 2006 Jun;129(Pt 6):1438-45
16670177
Am J Med Genet. 1995 Jun 5;57(2):361-4
7668363
Genomics. 2005 Sep;86(3):287-94
16033706
Am J Hum Genet. 2002 Feb;70(2):537-42
11727201
EMBO J. 1995 Aug 1;14(15):3599-608
7641679
Mol Ther. 2007 Mar;15(3):481-91
17180118
Neurobiol Dis. 2005 Feb;18(1):226-41
15649713
Neuropathol Appl Neurobiol. 1989 Jul-Aug;15(4):371-83
2779737
J Neurosci. 2000 Sep 15;20(18):6898-906
10995834
Eur J Neurosci. 2002 Dec;16(12):2291-6
12492423
Hum Mol Genet. 2004 Dec 1;13(23):2893-906
15459177
Biochim Biophys Acta. 2006 Oct;1762(10):890-7
16935476
Biochim Biophys Acta. 2009 Apr;1793(4):697-709
19084560
Mol Ther. 2006 Mar;13(3):538-47
16364693
J Neurosci Res. 2000 Oct 15;62(2):234-40
11020216
Eye (Lond). 2005 Dec;19(12):1306-12
15565184
J Neuropathol Exp Neurol. 2008 Jan;67(1):16-29
18091563
J Neurosci. 2007 Sep 12;27(37):9826-34
17855597
J Biol Chem. 2006 Feb 3;281(5):2784-94
16303764
Neurobiol Dis. 2008 Feb;29(2):306-15
17988881
Mol Genet Metab. 2006 Nov;89(3):254-60
16621647
Am J Hum Genet. 2006 Jun;78(6):988-98
16685649
Hum Gene Ther. 2008 May;19(5):463-74
18473686
Hum Mol Genet. 2002 Oct 15;11(22):2709-21
12374761
Mol Cell Neurosci. 2003 Feb;22(2):146-61
12676526
Mol Cell Neurosci. 2002 Apr;19(4):515-27
11988019
J Neurosci. 2006 Feb 1;26(5):1334-42
16452657
FEBS Lett. 2003 Mar 13;538(1-3):207-12
12633880
Neurobiol Dis. 2009 May;34(2):308-19
19385065
EMBO J. 2000 Jun 15;19(12):2786-92
10856224
Nat Genet. 1999 Oct;23(2):233-6
10508524
J Neurosci. 2004 Oct 13;24(41):9117-26
15483130
Mol Ther. 2005 Sep;12(3):413-21
15979943